Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease
Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease
本文は利用できません。元の情報源をご確認ください。
Ultragenyx’s gene therapy hits key endpoint in Phase 3 trial for blood ammonia disease
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.